AXSM Q4 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$196M+65.0% YoY

Gross Profit

$184M93.7% margin

Operating Income

-$29M-15.0% margin

Net Income

-$29M-14.6% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+14.6%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$690M

Total Liabilities

$602M

Stockholders' Equity

$88M

Cash & Equivalents

$323M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$196M	$119M	+65.0%
Gross Profit	$184M	$108M	+69.7%
Operating Income	-$29M	-$73M	+59.5%
Net Income	-$29M	-$75M	+61.9%

Revenue Segments

Product

$195M100%

Geographic Segments

UNITED STATES

$194M100%

Non-US

$353,0000%